Message #11 From:
NewsBot Date: October 11, 2006 06:00:00 AM
GLIF News Grant Life Sciences Enters into Memorandum of Understanding (MOU) with i+MED Laboratories Co. Ltd. to Distribute i+MED's Point-of-Care Rapid Diagnostic Tests Via Grant's Established Marketing Channels
LOS ANGELES--(BUSINESS WIRE)--
“This is the third partnership we
have announced in recent weeks, bearing strong testimony that we are
aggressively executing Grant’s new corporate
strategy, which includes driving the sales of our partners’
products through our own established, significant marketing channels.”
Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences
Grant Life Sciences Inc. (OTC BB: GLIF) announced today that it has
signed a Memorandum of Understanding (MOU) with Thailand-based i+MED
Laboratories Co. Ltd. to distribute i+MED’s
point-of-care rapid diagnostic tests via Grant’s
established marketing channels in India, Taiwan, Indonesia, Mexico,
Middle East and Africa and expand into other countries later.
The i+MED product portfolio to be distributed by Grant includes, but is
not limited to, the following rapid tests: drugs of abuse, pregnancy,
and infectious disease product lines.
“This is the third partnership we have
announced in recent weeks, bearing strong testimony that we are
aggressively executing Grant’s new corporate
strategy, which includes driving the sales of our partners’
products through our own established, significant marketing channels,”
said Hun-Chi Lin, Ph.D., Grant’s President
and Chief Scientist.
About i+MED Laboratories
Founded in 2001, i+MED Laboratories Co. Ltd. (www.imed.co.th)
is one of the leading diagnostics companies in Thailand. The company,
which develops, manufactures and distributes high-quality ‘rapid’
tests for Asian markets, is 46 percent owned by the Thai government’s
SME Venture Capital Fund.
About Grant Life Sciences
Grant Life Sciences Inc., a development stage company, engages in the
research, development, marketing, and sale of diagnostic kits for the
screening, monitoring, and diagnosis of diseases with emphasis on women’s
health, infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in
this press release are "forward-looking statements" that involve a
number of risks and uncertainties. The actual future results of Grant
Life Sciences could differ significantly from those statements. Factors
that could cause actual results to differ materially include risks and
uncertainties such as the inability to finance the company's operations
or expansion, inability to hire and retain qualified personnel, changes
in the general economic climate, including rising interest rates and
unanticipated events such as terrorist activities, results of clinical
trials, and market acceptance of the Company's products. In some cases,
"forward-looking statements" can be identified by terminology such as
"may," "will," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "predict," "potential" or "continue," or other comparable
terminology. Although Grant Life Sciences believes that the expectations
reflected in the "forward-looking" statements are reasonable, such
statements should not be regarded as a representation by the Company, or
any other person, that such "forward-looking statements" will be
achieved. Grant Life Sciences undertakes no duty to update any of the
"forward-looking statements," whether as a result of new information,
future events or otherwise. In light of the foregoing, readers are
cautioned not to place undue reliance on such "forward-looking
statements." For further risk factors associated with our Company,
review our SEC filings.
